Showing posts with label Pension. Show all posts
Showing posts with label Pension. Show all posts

Tuesday, July 17, 2007

TD Bank to chip in C$3.8 bln for BCE takeover

(Reuters) - TD said it has underwritten C$3.3 billion of a C$34.3-billion credit facility and also provided a C$500 million equity bridge facility to the buyout consortium, which is led by the Ontario Teachers' Pension Plan Board.




The consortium, which includes U.S. private equity firms Providence Equity Partners Inc. and Madison Dearborn Partners, LLC, was declared the winner of a bidding contest for BCE on June 30 with a C$34.8 billion all-cash offer.


Read more at Reuters.com Bonds News

Friday, June 29, 2007

CORRECTED: Path for generic biologics clears U.S. Senate panel

(Reuters) - WASHINGTON - A U.S. Senate panel voted on Wednesday to set a path for generic drugmakers to seek approval of cheaper, copycat versions of expensive biotechnology medicines.




Brand-name manufacturers would receive 12 years of exclusive marketing time before generic competition could start under a bill that cleared the Senate Health, Education, Labor and Pensions Committee by a voice vote.


Read more at Reuters.com Government Filings News

Darling Inherits a Fraying U.K. Economy as Brown's Successor at Treasury

(Bloomberg) -- Alistair Darling, Britain's new
chancellor of the exchequer, faces what may be the toughest task
in Prime Minister Gordon Brown's government: steering a fraying
economy with Brown looking over his shoulder.

Brown, who as chancellor oversaw the longest expansion in
two centuries, appointed the 53-year-old Darling as his
successor yesterday. Darling worked under Brown at the Treasury
in 1997, then ran the Departments of Trade and Industry and of
Work and Pensions for former Prime Minister Tony Blair.


Read more at Bloomberg Exclusive News

Wednesday, June 27, 2007

Path for generic biologics clears US Senate panel

(Reuters) - WASHINGTON, June 27 - A U.S. Senate panel voted on Wednesday to set a path for generic drugmakers to seek approval of cheaper, copycat versions of expensive biotechnology medicines.



Brand-name manufacturers would receive 12 years of exclusive marketing time before generic competition could start under a bill that cleared the Senate Health, Education, Labor and Pensions Committee by a voice vote.


Read more at Reuters.com Government Filings News